KR20240124927A - Ep4 길항제의 결정질 염 형태 - Google Patents

Ep4 길항제의 결정질 염 형태 Download PDF

Info

Publication number
KR20240124927A
KR20240124927A KR1020247020974A KR20247020974A KR20240124927A KR 20240124927 A KR20240124927 A KR 20240124927A KR 1020247020974 A KR1020247020974 A KR 1020247020974A KR 20247020974 A KR20247020974 A KR 20247020974A KR 20240124927 A KR20240124927 A KR 20240124927A
Authority
KR
South Korea
Prior art keywords
compound
cancer
free acid
crystalline free
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247020974A
Other languages
English (en)
Korean (ko)
Inventor
파리드 베나유드
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20240124927A publication Critical patent/KR20240124927A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247020974A 2021-12-23 2022-12-22 Ep4 길항제의 결정질 염 형태 Pending KR20240124927A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163293183P 2021-12-23 2021-12-23
US63/293,183 2021-12-23
PCT/US2022/053842 WO2023122289A1 (en) 2021-12-23 2022-12-22 Crystalline salt form of ep4 antagonist

Publications (1)

Publication Number Publication Date
KR20240124927A true KR20240124927A (ko) 2024-08-19

Family

ID=85222399

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247020974A Pending KR20240124927A (ko) 2021-12-23 2022-12-22 Ep4 길항제의 결정질 염 형태

Country Status (7)

Country Link
US (1) US20250051285A1 (enExample)
EP (1) EP4452949A1 (enExample)
JP (1) JP2024545695A (enExample)
KR (1) KR20240124927A (enExample)
CN (1) CN118414328A (enExample)
CA (1) CA3242277A1 (enExample)
WO (1) WO2023122289A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061751A1 (en) 2010-09-21 2016-08-31 Eisai R&D Management Co., Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
JP2024545695A (ja) 2024-12-10
CA3242277A1 (en) 2023-06-29
WO2023122289A1 (en) 2023-06-29
US20250051285A1 (en) 2025-02-13
CN118414328A (zh) 2024-07-30
EP4452949A1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
US10710987B2 (en) Hydrochloride salt form for EZH2 inhibition
AU2009220856B2 (en) Crystal form of phenylamino pyrimidine derivative
WO2019042444A1 (zh) 一类抑制并降解酪氨酸蛋白激酶alk的化合物
CA3016830A1 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
KR20240145475A (ko) 고형 종양의 치료를 위한 유비퀴틴-특이적-프로세싱 프로테아제 1 (usp1) 억제제
AU2025202624A1 (en) Polymorphic forms of compound and preparation method therefor and application thereof
JP2002514647A (ja) メタロプロテイナーゼ阻害薬としての新規な置換アリールヒドロキサム酸
US20250051285A1 (en) Crystalline salt form of ep4 antagonist
WO2019189766A1 (ja) 新規ビアリールアミド誘導体
JP6463874B2 (ja) 医学的適用用の３−（１，２，４−トリアゾロ［４，３−ａ］ピリジン−３−イルエチニル）−４−メチル−Ｎ−（４−（（４−メチルピペラジン−１−イル）メチル）−３−トリフルオロメチルフェニル）ベンズアミドの新規な結晶性塩形態
EP4434986A1 (en) 15-pgdh inhibitor and use thereof
CN103833730B (zh) 苯并五元氮杂环基哌啶衍生物、其制备方法及其用途
JP7590550B2 (ja) ピラゾロピリジン系化合物の結晶及びその調製方法
RU2838463C2 (ru) Акрилсодержащие модуляторы ядерного транспорта и их применение
CN118459465A (zh) 氘代稠合杂环化合物及其制备方法和药物组合物、结合物及应用
HK40109783A (en) Hydrochloride salt form for ezh2 inhibition
WO2021254464A1 (zh) 取代喹唑啉类化合物、其制备方法、药物组合及应用
WO2022243573A1 (en) 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use
JP3197495B2 (ja) ピロリルベンズイミダゾール誘導体
CN102336740B (zh) 一类咪唑类化合物及其用途
CN117946165A (zh) 一种新型结构化合物axl抑制剂及其应用
JPH04279586A (ja) キサンチン誘導体
KR20210040228A (ko) 항히스타민 화합물, 이들의 약학 조성물 및 의약 용도
NZ718201B2 (en) Hydrochloride salt form for ezh2 inhibition

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000